Anagliptin twice-daily regimen improves glycaemic variability in subjects with type 2 diabetes: A double-blind, randomized controlled trial.

Yong-Ho Lee,Doo-Man Kim,Jae Myung Yu,Kyung Mook Choi,Sin Gon Kim,Kang Seo Park,Hyun-Shik Son,Choon Hee Chung,Kyu Jeung Ahn,Soon Hee Lee,Ki-Ho Song,Su Kyoung Kwon,Hyeong Kyu Park,Kyu Chang Won,Hak Chul Jang

Diabetes, obesity & metabolism（2023）

引用 0|浏览33

暂无评分

摘要

The anagliptin BID regimen for the treatment of type 2 diabetes was superior in blood glucose control after dinner to improve glycaemic variability, as indicated by MAGE and TIR, but was equivalent to the QD regimen in terms of HbA1c and FPG.

查看译文

关键词

DPP-4 inhibitor,continuous glucose monitoring,glycaemic control,randomized controlled trial,type 2 diabetes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要